Senzime and Philips Medical Systems enter development and commercialization partnership

"This is a landmark agreement for Senzime. It will significantly expand our reach into new market segments and multiply our addressable opportunity by tens of thousands of hospitals worldwide. The commercial agreement will operate alongside our existing product portfolio and sales channels, and we expect it to accelerate the global adoption of our core technologies. Upon successful execution, I expect this relationship to become a major contributor to Senzime’s revenues and earnings over the medium to long term. By leveraging our innovations through strategic industry partnerships such as this, we can access market segments that would otherwise be difficult to reach," said Philip Siberg, CEO of Senzime.

To date, Senzime’s monitoring solutions have been used on more than one million patients and are marketed through the company’s direct sales organization in the United States and Germany, as well as through distribution and license partners in more than 30 additional countries. The new agreement with Philips Medical Systems complements Senzime’s existing commercial strategy and is expected to generate new revenue streams through Philips’ extensive sales channels.